




A. Immunization of LN229/mCD39




B. Production of Hybridomas





























C. Screening of supernatants by flow cytometry



D. Cloning of Hybridomas



A**B**

A**Concentration ($\mu\text{g/ml}$)****J774-1****1****0.1****0.01****0.001****C₃₉Mab-1****Cell number****C₃₉Mab-2****Anti-CD39
mAb (5F2)****Fluorescence intensity****B****Concentration ($\mu\text{g/ml}$)****L1210****1****0.1****0.01****0.001****C₃₉Mab-1****Cell number****C₃₉Mab-2****Anti-CD39
mAb (5F2)****Fluorescence intensity**

